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INTRODUCTION
The sympathetic nervous system (SNS) is important
in cardiac pathophysiology. By increasing heart rate and
arterial blood pressure, the SNS plays a central role to
adapt cardiac performance to conditions of increased
external needs.1 Accordingly, a sympathetic surge
instantaneously ameliorates left ventricular (LV) con-
tractility and relaxation, abruptly increasing cardiac
working capacities. However, while an elevated sym-
pathetic tone may be beneficial in the short term, a
chronic elevation of SNS activity, as in the case of
congestive heart failure (CHF), has been clearly asso-
ciated with a significantly higher rate of adverse
events.2,3 Accordingly, an accurate evaluation of cardiac
SNS activity has become a sine qua non in modern
clinical cardiology. However, most of the techniques for
the assessment of cardiac sympathetic tone (i.e., barore-
flex sensitivity) offer an indirect estimation of its level
of activation.4 Nuclear cardiac imaging has been con-
sidered the reference standard for the evaluation of
cardiac innervation, allowing the evaluation of SNS
activity in (semi)-quantitative terms. Therefore, in the
last decades, both positron emission tomography (PET)5
and conventional nuclear imaging techniques [either
planar scintigraphy or single-photon emission computed
tomography (SPECT)] have been demonstrated to allow
the characterization of cardiac sympathetic innervation.6
On one hand, PET imaging, with its higher image
resolution, radiotracers’ versatility, and intrinsically
quantitative nature, is widely considered the quality
standard of cardiac SNS evaluation. On the other hand,
conventional nuclear imaging, with its robustness,
availability, and relatively limited operational costs,
still represents the most frequently performed imaging
test for cardiac innervation imaging. More specifically,
despite the theoretical advantages of more refined
techniques (i.e., PET and SPECT), planar scintigraphy
with 123I-metaiodobenzylguanidine (123I-MIBG)
remains the workhorse of innervation imaging. Conse-
quently, after almost 30 years from their introduction in
the research arena, the two measures of cardiac sympa-
thetic tone derived at planar scintigraphy, namely the
heart-to-mediastinum (H/M) ratio and the washout rate
of 123I-MIBG, still represent the most validated mea-
sures of LV innervation that are available, with the H/M
ratio as reference standard.7 So, a depressed H/M ratio
of 123I-MIBG has been shown to associate with a
significantly worse prognosis, independently of LV
ejection fraction.3 Moreover, in those years, a plethora
of small-numbered studies have demonstrated the asso-
ciation between abnormal H/M values and various
measures of LV structural and functional impairment,
almost translating it as a universal marker of cardiac
risk. Nevertheless, despite these apparently promising
results, cardiac innervation imaging has a minimal, if
any, clinical role in western countries, with currently no
indications in major clinical guidelines, except for
Japan.
In order to understand this, some of the most
evident limitations of cardiac 123I-MIBG imaging should
be carefully considered.
Standardization of Protocol
The scan protocol that is used for 123I-MIBG planar
imaging varies widely, with the delayed acquisition—
the clinically relevant one—more often performed
4 hours after tracer injection.7 However, this rather
lengthy imaging protocol ends up consistently affecting
patients’ compliance, reducing the possible throughput
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of the technique, and discouraging the performance of
additional, albeit time-consuming, dedicated cardiac
acquisitions (i.e., SPECT when performed with tradi-
tional Anger cameras).
Interestingly, the specifics of this apparently stan-
dardized protocol are based more on habits than on
experimental proof. In fact, solid evidence has demon-
strated that the real kinetics of 123I-MIBG in human
hearts is consistently more rapid than initially hypoth-
esized,8 theoretically allowing a significantly faster
image protocol, with the late scan performed even 1
hour after tracer administration.9
Instrumentation
It has been demonstrated that, due to the specific
emission spectrum of 123I-photons, medium-energy
collimators should be better used for cardiac 123I-MIBG
imaging, in order to obtain both high-quality images and
accurate estimates of the H/M ratio.10 However, the
majority of the diagnostic and prognostic data regarding
123I-MIBG imaging, including the ones coming from the
ADMIRE-HF study,3 have been obtained with low-
energy collimators, making the validity of the results
obtained somehow questionable.
For similar reasons, no clinically useful cut-off
value of H/M ratio has yet been proposed, since the most
frequently used normalcy value of 1.6 (derived from 202
historical controls gathered from 7 studies)11 has been
only validated in patients with CHF, demonstrating,
anyway, an unsatisfactory diagnostic accuracy as a
biomarker of cardiac risk.
The elevated methodological inhomogeneity of
123I-MIBG reports is even more evident when studies
performed, for instance, in Japan and Europe/US are
compared, with the former often using different instru-
mentation and scanning protocols (i.e., medium-energy
collimators). These technical disparities may allow to
question the generalizability of the many analysis of
pooled 123I-MIBG data derived from studies performed
in population of patients with different ethnicities
(Caucasian vs Asiatic) and imaged in different scanning
conditions.12
All together, these basic technical disadvantages of
planar 123I-MIBG imaging allow to question the role of
cardiac innervation parameters as clinically useful
biomarkers of cardiac risk. While more elegant imaging
techniques are available—SPECT and PET—they are
even less validated than planar imaging and are rarely
employed for clinical purposes. According to the
authors’ beliefs, a redefinition of the role of cardiac
sympathetic innervation imaging is eagerly needed,
clearly identifying the methodology to be used and the
specific fields of application.
In this respect, the most relevant limitations of
current cardiac innervation imaging modalities in speci-
fic clinical settings (i.e., CHF and ventricular
arrhythmias) will be further discussed.
CARDIAC INNERVATION IMAGING IN HEART
FAILURE: CHANCES AND LIMITS
SNS plays a central role in the genesis and
maintenance of CHF. In fact, evidence has conclusively
demonstrated that an increased SNS activity is not only
associated with the presence of CHF, but rather repre-
sent one of its most prominent (con)-causative factors.4
In the last decades, nuclear cardiac imaging has allowed
the characterization of the interaction between sympa-
thetic dysregulation and abnormal LV function, showing
that patients with CHF typically present a condition of
SNS hyper-activation coupled with post-synaptic
myocardial sympathetic desensitization, due to reduced
beta-adrenoceptor density and catecholamine spill-
over.3,13 In this respect, despite a number of small
mechanistic studies have suggested the possible value of
cardiac innervation imaging in the risk stratification and
management of patients with CHF, the most solid
evidence in favor of its application in clinical practice
comes from the ADMIRE-HF study.3 By enrolling
nearly one thousand subjects with depressed LV ejection
fraction and moderately symptomatic CHF (NYHA
class II-III) of mixed etiology (66% ischemic and 34%
non-ischemic), the ADMIRE-HF study demonstrated
that the H/M ratio of 123I-MIBG was able to risk-stratify
patients independently of other commonly measured
cardiac functional parameters, such as LV ejection
fraction and BNP. However, in order to be introduced in
clinical practice, any biomarker must have a number of
necessary qualities that should be always taken into
account: a cut-off value characterized by a relevant
accuracy in unmasking high-risk patients, the clear
definition of the categories of patients where it should be
applied, and the demonstration of its significant impact
on patient management in terms of either prognosis or
cost-benefit. Accordingly, despite the encouraging
results coming from ADMIRE-HF, relevant limitations
of the studies performed so far have prevented the
clinical application of cardiac innervation imaging. First
of all, no real cut-off of H/M ratio actually exists. In
fact, the H/M ratio is rather characterized by a contin-
uous association with patients risk14 and the cut-off
values proposed so far have only shown a modest
diagnostic accuracy in discriminating patients’ risk
categories.15 Moreover, while the ADMIRE-HF trial
was designed to include only patients with severely
compromised LV systolic function, it was demonstrated
that 43% of them had a LV ejection fraction[35% at
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core-lab analysis,16 making the main results of the study
rather questionable and a clear definition of the category
of patients that may benefit from innervation imaging
still lacking.
However, the prominent limitation of the existing
literature regarding cardiac SNS imaging is that it lacks a
prospective evaluation of the prognostic impact of inner-
vation parameters on clinical decision-making and patient
management. In fact, as in the case of any biomarker, it
should be determined whether measures of cardiac
sympathetic tone may be used to guide and monitor
therapeutic interventions, helping the clinician to prog-
nosticate the result of specific therapies and to decide, for
instance, on the non-use of an otherwise indicated
strategies. To date, only few studies performed in patients
mainly suffering from CHF have evaluated how cardiac
sympathetic innervation parameters might predict patient
response to selected cardioactive treatments, suggesting
the existence of some correlation between measures of
innervation at baseline and the effect of the therapies.17,18
However, most of those reports did not assess true patient
outcomes but rather surrogate endpoint of treatment
efficacy (i.e., change in LV ejection fraction)17 and were
not randomizing patients to strategies with and without
innervation imaging.18
After all those years, all the different disease-
modifying therapeutic strategies that can be adopted in
patients with CHF are only selected according to the
presence of classical cardiac structural and functional
abnormalities (i.e., ECG abnormalities or a depressed LV
ejection fraction), disregarding any parameter of sym-
pathetic innervation. In other words, despite the existing
evidence, no one would ever exclude any patient with
CHF from a given treatment, either pharmacological or
device-based [i.e., cardiac resynchronization therapy
(CRT)], based on the findings of cardiac innervation
imaging, such as a depressed H/M ratio of 123I-MIBG.
More innovative imaging techniques, such as SPECT
acquisition particularly if performed with dedicated CZT
devices, might allow to overcome some of the limitations
of planar 123I-MIBG scans, giving the opportunity to
obtain a three-dimensional measures of cardiac sympa-
thetic tone despite a contained acquisition time.18
However, a reliable prospective validation of the added
value of such imaging modalities in the management of
CHF is eagerly awaited.
INNERVATION IMAGING IN PATIENTS WITH
IHD AND INCREASED CARDIAC RISK
Sympathetic nervous terminals are significantly
more sensitive to ischemia than myocardial cells. In
fact, after an acute myocardial infarction, the area of LV
sympathetic denervation typically exceeds the extent of
myocardial necrosis.19 Thereafter, during the recovery
phase, autonomic nerve terminals sprout from the
borderzone of the infarction with progressive cardiac
reinnervation. However, the healing process is fre-
quently incoherent, leading to the formation of islands of
viable but denervated myocardium surrounded by hyper-
innervated regions that ultimately represent possible
sites of origin of malignant ventricular arrhythmias.20
Accordingly, it is not surprising that measures of
cardiac sympathetic denervation have been repeatedly
associated with an increased risk of arrhythmic events,
possibly helping to better risk-stratify cardiac patients.
Specifically, results coming from the ADMIRE-HF
study have shown that patients with a H/M ratio\1.6
had a significantly higher incidence of malignant ven-
tricular arrhythmic episodes, even fatal, than those with
a relatively preserved cardiac sympathetic tone.3 How-
ever, despite some initially encouraging data, 123I-MIBG
scintigraphy has proved to be a rather inaccurate method
for the prediction of malignant ventricular arrhythmias,
since patients with a preserved innervation (i.e., H/M
ratio[1.6) still have a significant incidence of arrhyth-
mic events or sudden cardiac deaths (roughly 3% in the
ADMIRE-HF cohort), and does not select patients that
may have improved survival with implantable car-
dioverter defibrillator (ICD) implantation.17 Therefore,
for many categories of patients, the presence of a
significantly depressed LV ejection fraction (i.e., less
than 30%-35%) is frequently considered the only indi-
cation for ICD therapy.
Interestingly, after many years, the currently on-
going ADMIRE-ICD study (NCT02656329) will be the
first randomized trial to evaluate the efficacy of 123I-
MIBG imaging for guiding the decision of ICD implan-
tation. However, since this study will only enroll
patients with a narrow range of EF values (between
30% and 35%), it could, curiously, further limit the
categories of patients that could benefit from cardiac
innervation imaging.
In this scenario, planar scintigraphy badly adapts to
appropriately describe the patterns of cardiac sympa-
thetic denervation in patients with IHD and post-
ischemic LV dysfunction who frequently show areas of
viable myocardium interposed within scarred regions. In
fact, limited evidence has suggested that the use of
tomographic imaging techniques, such as SPECT or
PET, would allow an accurate depiction of the regional
distribution of sympathetic nerve terminals and a better
risk stratification than traditional planar measures.19
Moreover, by integrating information coming also from
the evaluation of myocardial perfusion data, the inner-
vation imaging of the future will probably allow the
combined assessment of two of the most relevant cardiac
functional parameters and the accurate localization of the
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areas of viable myocardium showing a depressed sym-
pathetic innervation. In fact, the presence of those
myocardial regions showing an ‘‘innervation/perfusion
mismatch’’ (i.e., at the border zone of myocardial scars),
representing preferred sites of origin of malignant
ventricular arrhythmias,20 has been clearly associated
with adverse patients’ prognosis.19 An elevated regional
burden of jeopardized myocardium with impaired sym-
pathetic innervation may possibly represent an additional
marker of risk in patients with IHD, possibly predicting
the need for aggressive therapeutic strategies.19,20 Nev-
ertheless, while the possible clinical impact of those
innovative parameters of regional sympathetic denerva-
tion has been recently suggested by some small studies,
an appropriate validation of this diagnostic approach is
still awaited and the current clinical role of innervation
imaging in the management of patients at risk of
malignant ventricular arrhythmias almost inexistent.
CONCLUSION
Nuclear cardiac imaging is the only accurate tool
for the assessment of the interaction between LV
sympathetic innervation and cardiac function. Among
the different methodologies that have been proposed, a
rather rudimentary technique, namely planar 123I-MIBG
scintigraphy, still remains the state-of-the-art for the
evaluation of cardiac sympathetic innervation. However,
while evidence has been accumulating on the possible
role of innervation imaging for the risk stratification and
disease management of cardiac patients, none of these
techniques has never reached the clinical arena and is
mainly considered a purely research investigation. A
number of reasons may justify this apparent conundrum.
First of all, large trials focused on specific categories of
patients to clearly identify the possible fields of appli-
cations of cardiac innervation imaging (i.e.,
management of patients with borderline indication for
ICD implantation or selection of patients with malignant
ventricular arrhythmias undergoing invasive procedures)
are still lacking. On the other hand, the panel of
clinically available nuclear techniques should be further
implemented, with the progressive abandonment of
‘‘old-fashioned’’ methodologies and measures (i.e., H/
M ratio of 123I-MIBG), and the introduction of innova-
tive markers of risk obtained with novel technologies
(i.e., CZT cameras), such as the regional extent of LV
sympathetic denervation or the burden of innervation/
perfusion mismatch.
Otherwise, it is conceivable that nuclear innervation
imaging will remain one of the ‘‘holy grails’’ of modern
cardiology, with a solid pathophysiologic background
but limited, if any, clinical applications and patients will
be further treated according to other biomarkers, such as
LV ejection fraction.
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